GlassScriptPhysician profile
Nilanee A Karikaran
NPI 1114008927
$13,700.14
in general payments reported to CMS, 2019-2025
56 companies · $1,996 in 2025
The $1,996 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,875 · 2020: $505 · 2021: $1,342 · 2022: $1,712 · 2023: $1,491 · 2024: $1,779 · 2025: $1,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,167 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,167.30 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $3,735.34 | 2019 | |
| Abbvie INC. | $912.94 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $704.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $638.98 | 2019-2025 | |
| Ucb, INC. | $566.03 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $554.35 | 2020-2025 | Austedo Xr, Ajovy, Austedo |
| Lilly USA, LLC | $544.11 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Alexion Pharmaceuticals, INC. | $430.01 | 2019-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $429.68 | 2021-2024 | Xcopri |
| Pfizer INC. | $408.34 | 2019-2025 | |
| Biogen, INC. | $353.73 | 2019-2025 | Vumerity, Tysabri |
| Acadia Pharmaceuticals INC | $286.40 | 2019-2025 | Daybue, Nuplazid |
| Mallinckrodt Hospital Products INC. | $281.07 | 2021-2022 | |
| Neurelis, INC. | $247.56 | 2020-2025 | Valtoco |
| Argenx US, INC. | $245.17 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilanee Karikaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.